CSIMarket Company Name, Ticker, Industry, else..
 
Calcimedica Inc   (NASDAQ: CALC)
Other Ticker:  
 
 
Price: $2.7300 $-0.16 -5.536%
Day's High: $3.0375 Week Perf: -11.65 %
Day's Low: $ 2.61 30 Day Perf: -1.09 %
Volume (M): 60 52 Wk High: $ 8.38
Volume (M$): $ 163 52 Wk Avg: $4.33
Open: $2.89 52 Wk Low: $2.55



 Market Capitalization (Millions $) 30
 Shares Outstanding (Millions) 11
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -14
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 0

Calcimedica Inc
Calcimedica Inc is a biopharmaceutical company that focuses on the discovery and development of novel calcium channel inhibitors for the treatment of various diseases. The company's mission is to provide safer and more effective therapeutic options for patients with unmet medical needs. Calcimedica's research and development efforts revolve around leveraging the role of calcium signaling in disease pathways, with a specific focus on immune, neurological, and fibrotic disorders. By targeting calcium channels, the company aims to modulate cellular responses and restore normal physiological functions. Calcimedica's innovative approach has the potential to address a wide range of diseases and improve patient outcomes.


   Company Address: 505 Coast Boulevard South La Jolla 92037 CA
   Company Phone Number: 952-5500   Stock Exchange / Ticker: NASDAQ CALC


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV      % 
ABT      % 
BMY      % 
JNJ      % 
MRK      % 
PFE      % 
• View Complete Report
   



Stocks on the Move

Evaluating CalciMedica Inc.s Market Challenges and Potential Upside Amidst Industry Setbacks

Published Mon, Aug 5 2024 4:02 PM UTC

As CalciMedica Inc. (NASDAQ: CALC) continues to navigate the complexities of being a clinical-stage biopharmaceutical company, recent developments highlight significant challenges as well as intra-industry competition impacting its market performance. In the last trading session, CALC shares demonstrated a notable slowdown, trailing behind broader market trends, and raising ...
Stocks on the Move

CalciMedicas Breakthrough Treatment Offers Hope for Acute Pancreatitis Patients

Published Sun, Jun 30 2024 12:46 PM UTC

CalciMedica Inc, a clinical-stage biopharmaceutical company specializing in the development of novel calcium release-activated calcium (CRAC) channel inhibitors, is making significant strides in the field of acute pancreatitis (AP) treatment. The company recently announced positive topline data from its Phase 2b CARPO trial, evaluating the efficacy of Auxora in AP patients w...
Calcimedica Inc

Calcimedica Inc Reports Growth in Earnings and Progress in the Third Quarter of 2023

The stock market is a constantly shifting landscape, where big players in the Major Pharmaceutical Preparations sector dominate the scene. However, it's always exciting to see smaller entities making a splash with their earnings. One such company, Calcimedica Inc, has recently revealed some intriguing figures.
In the third quarter of 2023, Calcimedica Inc reported an operating deficit of $-4.833 million. While this may sound discouraging at first glance, it's important to consider the bigger picture. Looking back at the corresponding period a year before, it becomes evident that Calcimedica Inc has made strides in improving its productivity. This is especially noteworthy since the company primarily operates in the progress stage.
Calcimedica Inc

Calcimedica Inc. Emerges Victorious with Operating Loss Cut by $8.301 Million in Q2 2023, Cementing its Leadership in the Major Pharmaceutical Preparations Industry

Calcimedica Inc, a major player in the pharmaceutical preparations sector, has recently released its second-quarter numbers for 2023. While the company has not disclosed any revenue figures yet, market veterans have analyzed the operating loss of -$6.583 million for the reporting season spanning from April to June 30, 2023. This unexpected positive surprise, without the usual comparisons, marks a significant improvement from the operating loss of -$8.301 million reported during the same period last year. The improved performance in reducing operating losses to -$6.304 million has instilled confidence in market participants regarding Calcimedica Inc (CALC).
Recent fiscal period executive operations have exhibited a higher level of competence, resulting in the reduction of diminishing returns. These positive developments have undoubtedly contributed to the boost in market confidence. Investors will closely observe and anticipate Calcimedica Inc's next financial results, set to be reported on March 7, 2024.
Calcimedica Inc

Major Pharmaceutical Preparations Giant Faces Operating Crisis in Q1 2023

Investors and stock market insiders have been keeping a close eye on the Major Pharmaceutical Preparations sector's first quarter of 2023 performance, and there's no doubt that it's been a topic of discussion among those in the know. With an operating shortfall of $-22.34 million, it's clear that the company has yet to specify any revenue for the January to March 31, 2023 financial reporting period.
But while this news may sound concerning on the surface, it's important to note that the company has taken measurable steps to address the shortfall and ensure that their business can continue to thrive in the current economic climate. Specifically, the management team has pursued distinct financial plans to get things back on track.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com